Regenxbio Inc (STU:RB0) Stock News, Headlines & Updates
Regenxbio Inc Stock News from GuruFocus
- 1
Jul 10, 2025
REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy | RG
GuruFocus News • 11:15am
REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy
PRNewswire • 11:00am
Jun 16, 2025
Regenxbio (RGNX) Maintains Strong Outlook Amid Competitor Safety Concerns | RGNX Stock News
GuruFocus News • 12:15pm
Jun 13, 2025
REGENXBIO (RGNX) Prepares for Potential $4M Warrant Cash Influx
GuruFocus News • 4:57pm
Regenxbio (RGNX) Proposes Sale of Over 268,000 Shares | RGNX Stock News
GuruFocus News • 4:45pm
Jun 09, 2025
Regenxbio (RGNX) Maintains Buy Rating with $52 Price Target | RGNX Stock News
GuruFocus News • 7:30am
Jun 05, 2025
Regenxbio (RGNX) Reports Positive Data for RGX-202 Gene Therapy Trial
GuruFocus News • 7:55am
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
PRNewswire • 7:00am
Regenxbio (RGNX) Reports Promising Interim Results for Duchenne Therapy | RGNX Stock News
GuruFocus News • 6:30am
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 | RGNX Stock News
GuruFocus News • 6:15am
Jun 02, 2025
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202
PRNewswire • 7:00am
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202 | RGNX Stock News
GuruFocus News • 6:15am
May 19, 2025
REGENXBIO (RGNX) Secures $250 Million Non-Dilutive Funding
GuruFocus News • 4:55pm
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million
PRNewswire • 4:00pm
Regenxbio (RGNX) Secures $250M Royalty Bond Deal for Non-Dilutive Funding | RGNX Stock News
GuruFocus News • 3:32pm
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million | RGNX Stock News
GuruFocus News • 3:16pm
May 14, 2025
FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment
PRNewswire • 7:00am
FDA Grants Priority Review to REGENXBIO's (RGNX) Gene Therapy for MPS II | RGNX Stock News
GuruFocus News • 6:45am
FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment | RGNX Stock News
GuruFocus News • 6:31am
May 13, 2025
REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II
PRNewswire • 7:00am
Regenxbio (RGNX) Gains FDA Priority Review for RGX-121 BLA | RGNX Stock News
GuruFocus News • 6:31am
REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II | RGNX Stock News
GuruFocus News • 6:16am
Regenxbio Inc (RGNX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and Financial Strength Propel Growth
GuruFocus News • 1:09am
Q1 2025 Regenxbio Inc Earnings Call Transcript
GuruFocus News • 11:02pm
May 12, 2025
REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights
PRNewswire • 4:00pm
REGENXBIO (RGNX) Reports Decrease in Q1 Revenue, Focuses on Gene Therapy Progress | RGNX Stock News
GuruFocus News • 3:59pm
REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights | RGNX Stock News
GuruFocus News • 3:20pm
May 09, 2025
What To Expect From Regenxbio Inc (RGNX) Q1 2025 Earnings
GuruFocus News • 7:38am
May 08, 2025
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
PRNewswire • 7:00am
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting | RGNX Stock News
GuruFocus News • 6:17am
May 06, 2025
REGENXBIO to Participate in Upcoming Investor Conferences
PRNewswire • 7:00am
REGENXBIO to Participate in Upcoming Investor Conferences | RGNX Stock News
GuruFocus News • 6:17am
May 01, 2025
BlackRock, Inc. Reduces Stake in Regenxbio Inc: A Strategic Portfolio Adjustment
GuruFocus News • 7:39pm
Apr 30, 2025
REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights
PRNewswire • 4:00pm
REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights | RGNX Stock News
GuruFocus News • 3:18pm
Apr 21, 2025
Regenxbio (RGNX) Gains Following Positive FDA Comments on Gene Therapies
GuruFocus News • 1:55pm
- 1
Show
Entries
Headlines
Total 0- 1
No recent news